Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Immunoglobulin Light-chain Amyloidosis 2Paraproteinemias 1Amyloidosis 1Alzheimer Disease 1

Interventions

Dexamethasone 27Melphalan 22Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 14Filgrastim 13Bortezomib 12Calcium Dobesilate 9Lenalidomide 7fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5Cyclosporine 5Thalidomide 4Interferon-alpha 4Etoposide 4Busulfan 4miridesap 3dexamethasone acetate 3Radiotherapy 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Carboplatin 3pomalidomide 2liposomal amphotericin B 2ixazomib 2daratumumab 2birtamimab 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Immunoglobulin Light-chain Amyloidosis × birtamimab × Clear all
NCT02632786 2019-04-05

PRONTO

Prothena Biosciences Ltd.

Phase 2 Completed
129 enrolled 18 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Paraproteinemias

NCT01707264 2018-08-28

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Prothena Biosciences Ltd.

Phase 1/2 Completed
69 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡